Oligomerix Awarded a Grant for its Alzheimer’s Drug Discovery Program Targeting Tau Oligomers from the National Institutes of Health

Oligomerix to Present at Biotech Showcase^TM 2014

Taconic and Oligomerix to Collaborate on Tau Mouse Model Characterization for Use in Alzheimer’s Disease Research

Identification of a Tau Oligomer Structure That is Toxic to Neurons

Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimer’s Disease Progression

Oligomerix, Inc. to Present Multiple Posters Highlighting its Tau-Focused Technology During the Annual Alzheimer’s Association International Conference

Oligomerix, Inc. Completes Series B Financing

Oligomerix, Inc. Completes $2 Million Series A Financing

SFN 2010 Press Release: Validation of Extracellular Tau Oligomer Target

Oligomerix Awarded Phase II NIH Grant to Discover Novel Drugs for Alzheimer’s Disease